FDA Grants Alexion's Soliris Orphan Status for Neuromuscular Disorder

By Dow Jones Business News, 

By Michael Calia

The U.S. Food and Drug Administration has granted orphan-drug status to Alexion Pharmaceuticals Inc.'s ( ALXN ) Soliris for the treatment of a rare neuromuscular disorder.

Alexion said it is enrolling participants for an international, placebo-controlled trial for patients with the refractory generalized form of the disorder, myasthenia gravis.

The drug isn't yet approved anywhere for treatment of myasthenia gravis, although it has received approval for the treatment of other rare disorders.

Myasthenia gravis is a debilitating neuromuscular disorder that leads to weakness in muscles, starting with the eye and progressing into other, larger muscle groups. It leads to weakness, slurred speech, and difficultly chewing, swallowing and breathing.

"By specifically inhibiting the terminal complement pathway, which is believed to play a pivotal role in the pathophysiology of MG, we believe that eculizumab has the potential to help patients living with this devastating rare disorder," Alexion executive Martin Mackay said in a press release.

The FDA grants orphan status to drugs and other products intended to treat, diagnose or prevent rare diseases and disorders affecting fewer than 200,000 people in the U.S.

Soliris, also called eculizumab, had already received an FDA orphan-drug designation earlier this year, for the prevention of delayed graft function in kidney-transplant patients.

Soliris is Alexion's only product on the market. In April, the company said Soliris sales in the first quarter jumped 67% over the prior-year period.

Write to Michael Calia at michael.calia@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

  (END) Dow Jones Newswires
  Copyright (c) 2014 Dow Jones & Company, Inc.

This article appears in: News Headlines

Referenced Stocks: ALXN

Dow Jones Business News

More from Dow Jones Business News:

Related Videos



Most Active by Volume

  • $16.09 ▲ 0.50%
  • $102.50 ▲ 0.24%
  • $19.57 ▲ 2.35%
  • $49.75 ▲ 0.65%
  • $34.92 ▲ 0.78%
  • $3.63 ▲ 0.83%
  • $13.06 ▼ 0.38%
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM